NCT03185611.

Trial name or title	Effectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Recurrence in Crohn's Disease
Methods	RCT, parallel design, multi‐centre study, single blinded (Outcomes Assessor); Location: China
Participants	120 participants, aged 18 to 65 years Inclusion criteria: Consecutive patients with Crohn's disease undergoing intestinal resection of all macroscopic diseased bowel, with an endoscopically accessible ileocolic anastomosis; Enrolled patients must have one or more risk factor for the development of postoperative recurrence including penetrating disease behaviour, prior bowel resection, and active smoking. Exclusion criteria: Severe co‐morbidities; With a stoma; With malignancy; Pregnancy; Intolerant of thiopurine drugs; With contraindication of using rifaximin or thiopurine drug
Interventions	Two arms; Arm 1: Prescribed Rifaximin (600mg, twice daily) combined with Azathioprine (2.0‐2.5mg/kg/day) for 3 months after surgery, and then Azathioprine monotherapy (2.0 to 2.5 mg/kg/day) for the next 3 months and Arm 2: Prescribed Azathioprine (2.0 to 2.5 mg/kg/day) for 6 months after surgery
Outcomes	Primary: Incidence of endoscopic recurrence 6 months after surgery Secondary: Adverse effect
Starting date	June 14, 2017
Contact information	Xiang Gao, MD, PhD; gaoxiangmed@163.com
Notes